This article originally appeared in the Financial Post. By Nigel Rawson and John Adams, January 24, 2023 Forty years ago ...
By Nigel Rawson and John Adams, November 23, 2022 For seven years, the Patented Medicines Prices Review Board (PMPRB) – ...
This article originally appeared in the Financial Post. By Nigel Rawson and John Adams, November 2, 2022 This month marks ...
By Nigel Rawson and John Adams, May 2, 2022 On April 14, 2022, Health Minister Jean-Yves Duclos announced the federal ...
This article originally appeared in the Financial Post. By Nigel Rawson and John Adams, April 22, 2022 After being late to ...
OTTAWA, ON (April 11, 2022): We are pleased to announce that Nigel Rawson and John Adams will be joining the ...
By Nigel Rawson and John Adams, March 24, 2022 Much has been written over the last few years about the ...
A new MLI commentary warns that pending and aggressive drug price control efforts could lead to major unintended consequences in ...
Advocates for national pharmacare who insist on control of drug prices, not by negotiation but by federal regulation, may have ...
The Appeal Court’s unanimous decision demonstrates that the Patented Medicine Prices Review Board is out of control in an anti-industry, ...
OTTAWA, ON (June 3, 2021): The COVID-19 pandemic has unmasked a dangerous lack of investment in pharmaceutical and vaccine research, development, and ...
The COVID-19 pandemic has cost lives and caused much fear in Canada. With Canadians now eagerly waiting for vaccines, Nigel ...
